States restrict Medicaid coverage for GLP-1 weight-loss drugs amid rising costs
Several states have ended Medicaid coverage for GLP-1 drugs, citing unsustainable costs despite rising obesity rates.
2 min read
live feed
#wire#us+3 more
Several states have ended Medicaid coverage for GLP-1 drugs, citing unsustainable costs despite rising obesity rates.
The Trump administration acknowledged a significant error in its Medicaid fraud probe figures for New York, undermining its anti-fraud campaign.